UK markets open in 6 hours 17 minutes
NIKKEI 225
37,749.31 -212.49 (-0.56%) HANG SENG
16,251.84 +2.87 (+0.02%) CRUDE OIL
82.73 +0.04 (+0.05%) GOLD FUTURES
2,384.30 -4.10 (-0.17%) DOW
37,753.31 -45.66 (-0.12%) Bitcoin GBP
49,191.17 -2,026.72 (-3.96%)
Syndax Pharmaceuticals, Inc. (SNDX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 21.28 |
| Open | 21.55 |
| Bid | 20.70 x 400 |
| Ask | 20.77 x 300 |
| Day's range | 20.58 - 21.55 |
| 52-week range | 11.22 - 25.34 |
| Volume | |
| Avg. volume | 1,153,122 |
| Market cap | 1.762B |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
- Simply Wall St.
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Insider Monkey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99. Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone. […]
© 2024 Yahoo. All rights reserved.